Review of radiopharmaceutical therapy in prostate cancer

Urologic Oncology Seminars and Original Investigations 2026 Open access

Read full text
Authors: Sean R. Miller, Yuni K. Dewaraja, Steven P. Rowe, Zachery Roger Reichert, Benjamin L. Viglianti
DOI: 10.1016/j.urolonc.2026.111030
Cited by: 1
References: 48

Abstract

Radiopharmaceuticals therapy (RPT) has been a major breakthrough in the treatment of prostate cancer. This therapy utilizes radioactive isotopes targeted specifically to prostate cancer, combining the advantages of systemic therapy with targeted radiation. The 2 currently FDA approved agents are 223 Ra and 177 Lu-PSMA-617 which have both demonstrated an overall survival advantage. In this review we will discuss the approved agents, their similarities and differences, treatment sequencing, combinations with other therapies, as well as future directions of this promising field.

Fields of Study & Subjects

Radiopharmaceutical Chemistry and Applications Prostate Cancer Treatment and Research Chemical Reactions and Isotopes

Publication details

Journal / source
Urologic Oncology Seminars and Original Investigations
Publisher
Elsevier BV
Volume
44
Issue
10
Pages
693–699
Publication date
18 February 2026
Language
EN